SCHEDULE 13G/A: Ariel Investments Discloses 26.9% Stake in Core Laboratories Inc.

Ariel Investments, LLC has filed an Amendment No. 7 to Schedule 13G, reporting a significant 26.9% beneficial ownership stake in Core Laboratories Inc.

Summary

• Ariel Investments, LLC reported beneficial ownership of 12,597,204 shares of Core Laboratories Inc. common stock as of May 31, 2025.
• This ownership represents 26.9% of the total class of Core Laboratories Inc. securities.
• Ariel Investments, LLC holds sole voting power over 11,883,289 shares and sole dispositive power over 12,597,204 shares.
• The filing is an Amendment No. 7 to a Schedule 13G, indicating an update to a previously reported passive ownership stake.
• Ariel Fund, a series of Ariel Investment Trust, an open-end management investment company, owns 5,219,278 shares of the Issuer, representing an economic interest in more than 5% of the subject securities.

Sentiment

Score: 5

Explanation: Factual disclosure of beneficial ownership, neutral in tone regarding company performance or outlook.

Positives

• Ariel Investments, LLC, a prominent investment adviser, maintains a substantial 26.9% beneficial ownership stake in Core Laboratories Inc., signaling strong conviction in the company's long-term value.
• The significant holding by Ariel Fund, a specific fund managed by Ariel Investments, further underscores a concentrated and potentially strategic investment in Core Laboratories Inc.

Stakeholder Impact

• Shareholders: The disclosure of a significant stake by a reputable institutional investor like Ariel Investments, LLC may be perceived as a vote of confidence, potentially influencing investor sentiment and the company's stock valuation.

Key Dates

Keywords

Core Laboratories Inc., Ariel Investments, Schedule 13G, Beneficial Ownership, Institutional Investor, Common Stock, Investment Adviser, Shareholding, SEC Filing